Rezdiffra (Resmetirom) Non-Responder Profile: Why It Doesn't Work for Everyone

What Rezdiffra Actually Is and How It Works

Rezdiffra is the first and, as of early 2025, only FDA-approved medication for metabolic dysfunction-associated steatohepatitis (MASH), which was previously called NASH. It works by selectively activating thyroid hormone receptor beta (THR-beta) in the liver. THR-beta activation increases fatty acid oxidation, reduces hepatic triglyceride synthesis, and lowers LDL cholesterol.

The mechanism matters for understanding non-response. If your liver's THR-beta signaling is not the rate-limiting step in your disease, resmetirom has less to act on. Women whose MASH is driven primarily by alcohol (even low-level use), drug toxicity, or autoimmune hepatitis are working with a fundamentally different disease biology.

How the Liver Responds in Women Across Life Stages

The liver is hormonally sensitive in ways that are still being mapped. Estrogen promotes hepatic fat export via VLDL and partially protects against de novo lipogenesis. Postmenopausal women show measurably higher hepatic fat fractions compared with age-matched premenopausal women, which is one reason MASH incidence rises sharply after menopause. This same hormonal shift may change how well THR-beta agonism works, though direct trial data stratified by menopausal status in MAESTRO-NASH have not been published.

Women with PCOS carry a two- to threefold higher prevalence of NAFLD/MASH compared with women without PCOS, driven by hyperinsulinemia, elevated androgens, and visceral adiposity. Whether this metabolic substrate makes them better or poorer resmetirom responders is not yet known. This is an evidence gap you deserve to know about.

The MAESTRO-NASH Trial: What the Numbers Actually Show

MAESTRO-NASH was the key Phase 3 trial that earned Rezdiffra its approval. It enrolled 966 adults with biopsy-confirmed MASH and fibrosis stages F1b through F3. At 52 weeks:

• MASH resolution without worsening fibrosis: 26% (80 mg) and 30% (100 mg) versus 10% placebo
• Fibrosis improvement by at least one stage: 24% (80 mg) and 26% (100 mg) versus 14% placebo
• Both co-primary endpoints reached statistical significance (p < 0.001)

The numbers are real. They are also not overwhelming. Roughly 70 percent of the 100 mg group did not achieve MASH resolution. That is not a failure of the drug per se; MASH is a stubborn, multifactorial disease. But it does mean that non-response is the statistical majority, not the exception.

Who Was Excluded from the Trial

Understanding who the trial excluded helps define who is unlikely to respond in practice:

• Patients with F4 (cirrhosis). The MAESTRO-NASH Outcomes trial is ongoing for this group.
• Patients with uncontrolled thyroid disease (TSH outside 0.5 to 5 mIU/L at screening)
• Patients with alcohol intake above 14 drinks per week (women) or 21 per week (men)
• Patients on thyroid hormone replacement who had not been on a stable dose for at least three months
• Active autoimmune hepatitis, viral hepatitis, or other competing liver diagnoses

If you fall into any of these categories, the evidence base for Rezdiffra simply does not include you.

Sex Composition in MAESTRO-NASH

Approximately 55 percent of MAESTRO-NASH participants were female, which is genuinely better representation than most liver-disease trials. The trial did not publish sex-stratified efficacy data in the primary paper, meaning we cannot say with precision whether women responded at the same rate as men. This is a meaningful gap. Female liver physiology differs across hormonal states, and a pooled response rate may obscure real subgroup differences.

The Non-Responder Profile: Who Is Least Likely to Benefit

Based on the trial exclusion criteria, the drug's mechanism, and early real-world signals, the following profile describes a woman who is less likely to respond to Rezdiffra. No single factor is absolute, and your clinician weighs the whole picture.

Factor 1: Fibrosis Stage F4 (Cirrhosis)

Rezdiffra is approved only for F2 to F3 fibrosis. Women with F4 cirrhosis were not included in MAESTRO-NASH. Decompensated cirrhosis (ascites, variceal bleeding, hepatic encephalopathy) is a contraindication listed in the FDA prescribing information. If your liver has already reached cirrhosis, the hepatic architecture is too altered for THR-beta agonism alone to reverse fibrosis, and the safety profile changes substantially.

Factor 2: Uncontrolled or Untreated Thyroid Disease

THR-beta is a thyroid hormone receptor. If your thyroid axis is dysregulated, adding a synthetic THR-beta agonist on top of an unstable hormonal background creates an unpredictable pharmacological environment. The prescribing label requires TSH monitoring at baseline and periodically during treatment. Women are five to eight times more likely than men to develop thyroid disorders, and autoimmune thyroid disease (Hashimoto thyroiditis, Graves disease) is particularly common in perimenopausal women. If your TSH is not stable before you start, response rates are unknown.

Factor 3: A Non-Metabolic Cause of Liver Disease

Resmetirom targets the metabolic driver of MASH: de novo lipogenesis, impaired beta-oxidation, and dyslipidemia. If your liver inflammation and fibrosis stem from a different cause, such as alcohol-associated liver disease, drug-induced liver injury, primary biliary cholangitis, or Wilson disease, then THR-beta agonism addresses the wrong pathway. MASH diagnosis must be confirmed, ideally by biopsy, before starting therapy.

Factor 4: Inadequate Metabolic Risk Factor Control

In MAESTRO-NASH, participants with the largest reductions in liver fat and ALT also tended to have meaningful improvements in body weight and metabolic markers. Women who have not achieved any reduction in caloric intake, remain sedentary, or have HbA1c persistently above 9 to 10 percent likely face an upstream metabolic load that resmetirom cannot fully counteract downstream. A 2023 analysis of NAFLD progression found that concurrent weight loss of even 5 percent amplified histologic response in combination treatment strategies. Resmetirom is not a substitute for metabolic management.

Factor 5: Drug Interactions That Blunt Efficacy or Raise Risk

Resmetirom is metabolized primarily via CYP3A4 and is also a substrate of OATP1B transporters. The prescribing information flags significant interactions with strong CYP3A4 inhibitors (such as clarithromycin and ketoconazole) and inducers (such as rifampin and carbamazepine). Women on hormonal contraceptives containing estrogen should note that resmetirom may alter their pharmacokinetics, though the clinical significance of this has not been directly quantified in women. Women on cyclosporine (used in autoimmune conditions more common in females) face a contraindication due to dramatically elevated resmetirom exposure.

Factor 6: Non-Adherence Driven by GI Side Effects

In MAESTRO-NASH, nausea occurred in 29% and diarrhea in 22% of the 100 mg group versus 13% and 13% in placebo. These are not trivial rates. Women in real-world reports on patient forums describe GI symptoms as the primary reason they reduced dose or stopped treatment entirely. If GI side effects cause you to miss frequent doses or stop in the first 8 to 12 weeks, the histologic benefit that accumulates slowly over months will not materialize. Non-adherence is functionally a non-response.

Real-World Signals: What Women Report

Randomized trial results and lived experience are not always the same thing. Women posting on liver disease forums and patient communities describe several patterns that align with the non-responder framework above.

A consistent theme: women who saw strong early reductions in ALT (by week 12) tended to report feeling more confident about continuing. Women who saw minimal ALT change by week 16 described uncertainty about whether to continue, particularly given the cost and side effect burden.

Another pattern: women with PCOS who were also on metformin or a GLP-1 receptor agonist reported more favorable early lipid and ALT changes than those on resmetirom alone. This is biologically plausible: GLP-1 agonists independently reduce hepatic fat, and the combination may address both the insulin resistance and THR-beta axes simultaneously. Formal combination trial data are not yet published.

Women going through perimenopause reported that managing symptoms like hot flashes, disrupted sleep, and fatigue made it harder to maintain the lifestyle changes that support resmetirom's efficacy, which is a practical reality the clinical trial setting does not capture.

Who This Drug Is Right For, and Who It Is Not

Likely Right For

• Women aged 30 to 65 with biopsy-confirmed MASH, F2 to F3 fibrosis, and metabolic-dysfunction drivers (obesity, type 2 diabetes, dyslipidemia, or metabolic syndrome)
• Perimenopausal and postmenopausal women where estrogen loss has accelerated hepatic fat accumulation on a background of metabolic disease
• Women with PCOS who have confirmed MASH on biopsy and have already optimized insulin sensitization
• Women whose ALT and liver fat imaging show objective improvement by 12 to 16 weeks on therapy

Likely Not Right For

• Women with F4 (cirrhosis) or decompensated liver disease
• Women with uncontrolled hypothyroidism or hyperthyroidism until thyroid status is stabilized
• Women with a competing cause of liver disease (alcohol-associated, autoimmune, viral, drug-induced)
• Women on cyclosporine or strong CYP3A4 inducers or inhibitors without specialist guidance
• Women who are pregnant or planning pregnancy in the near term (see pregnancy section below)
• Women who cannot manage or tolerate GI side effects sufficient to maintain 80 percent or greater adherence

Pregnancy, Lactation, and Contraception: Required Reading

Rezdiffra is contraindicated in pregnancy. This is not a relative caution. The FDA prescribing information states that resmetirom may cause fetal harm based on animal data. In animal reproductive toxicity studies, resmetirom caused embryo-fetal toxicity at exposures relevant to human therapeutic doses.

What This Means Across Life Stages

Reproductive years (roughly ages 18 to 45): If you are sexually active and capable of becoming pregnant, you must use reliable contraception throughout treatment. The label does not specify a washout period after stopping, but given that MASH is a chronic disease requiring long-term treatment, contraception planning should be part of every prescribing conversation.

Trying to conceive: Resmetirom should be discontinued before attempting conception. There are no human data on fetal outcomes after maternal resmetirom exposure. Given that MASH itself can impair fertility through metabolic and inflammatory pathways, the conversation with your hepatologist and reproductive endocrinologist needs to happen together, not in separate silos.

Pregnancy: Do not use. If you become pregnant during treatment, stop immediately and contact your obstetric provider. There is no registry for resmetirom pregnancy exposure yet. The National Pregnancy Registry for drugs in liver disease is a resource your provider can check for current enrollment options.

Postpartum and lactation: There are no human data on resmetirom transfer into breast milk. Animal lactation data are also not published in the prescribing label. Given the drug's mechanism and potential hepatic effects in a nursing infant, breastfeeding should be avoided during treatment. This decision significantly affects postpartum women managing MASH, and it deserves an explicit shared-decision conversation.

Perimenopause and post-menopause: Pregnancy risk is lower but not always zero in perimenopause. Women who have not confirmed surgical or natural menopause (12 consecutive months without menstruation) should still use contraception.

Monitoring: How to Know Sooner Whether You Are Responding

A non-responder who stays on a drug for two years without objective benefit carries cost, side effects, and opportunity cost. Early biochemical signals can guide the decision.

ALT is the most accessible surrogate marker. In MAESTRO-NASH, the 100 mg group showed mean ALT reductions of approximately 30 to 40 percent from baseline by week 24. If your ALT has not moved by 16 weeks despite full adherence and stable lifestyle, a frank conversation with your gastroenterologist or hepatologist about continuation is warranted.

MRI-PDFF (MRI-derived proton density fat fraction) is a non-invasive measure of hepatic fat. In MAESTRO-NASH, the 100 mg group showed approximately 10 percentage-point absolute reductions in liver fat fraction by week 24. If you have access to MRI-PDFF monitoring, a repeat scan at 24 weeks provides a more direct signal than ALT alone.

Lipid panels also shift: resmetirom reduces LDL by roughly 16 to 19 percent, a consistent pharmacodynamic effect that confirms the drug is biologically active in your liver even before histologic data are available.

What to Do If Rezdiffra Is Not Working for You

First, confirm the diagnosis is correct. Repeat liver biopsy or non-invasive fibrosis assessment (FibroScan, ELF test) may be appropriate if there is diagnostic uncertainty.

Second, audit adherence honestly. GI side effects, cost (Rezdiffra's list price is approximately $47,400 per year before insurance), and complexity of daily dosing all affect whether the drug is actually reaching your liver at therapeutic levels.

Third, assess metabolic cofactors. A 10 percent reduction in body weight is associated with MASH resolution in a meaningful subset of patients even without pharmacotherapy. If resmetirom is not delivering histologic improvement, adding or optimizing a GLP-1 receptor agonist, intensifying dietary intervention, or addressing untreated obstructive sleep apnea may shift the response field.

Fourth, discuss emerging combination trials. As of early 2025, several trials are evaluating resmetirom plus semaglutide and resmetirom plus other metabolic agents. Enrollment eligibility may be worth checking at clinicaltrials.gov if monotherapy is insufficient.

The Evidence Gap Women Should Know About

Women have been systematically underrepresented in liver disease trials for decades. MAESTRO-NASH was better than average at 55 percent female enrollment, but it still did not publish sex-stratified primary endpoints, hormonal-status subgroup analyses, or data on how menstrual cycle phase, hormonal contraceptive use, or menopausal transition affected ALT response or drug exposure.

The FDA's guidance on sex as a biological variable in clinical trials requires sponsors to analyze and report sex-disaggregated data, but MASH-specific guidance on hormonal subgroups does not yet exist. Until that data is published, any clinician who tells you that resmetirom's trial results apply equally to a 28-year-old woman with PCOS, a 51-year-old woman in menopause, and a 62-year-old postmenopausal woman with type 2 diabetes is extrapolating beyond the published evidence. That extrapolation may be reasonable. It is still extrapolation.

As a patient, you are entitled to ask your hepatologist: "Was the response rate in women the same as in men in MAESTRO-NASH?" The honest answer is: we do not know from published data. Plan your monitoring schedule and decision points accordingly.